Caution in interpreting biochemical control rates after treatment for prostate cancer: length of follow-up influences results

This publication has 24 references indexed in Scilit:

• Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
  JAMA, 1998
• Comparison of Radical Prostatectomy and Iodine 125 Interstitial Radiotherapy for the Treatment of Clinically Localized Prostate Cancer: A 7-Year Biochemical (PSA) Progression Analysis
  Urology, 1998
• Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions
  International Journal of Radiation Oncology*Biology*Physics, 1998
• Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy
  International Journal of Radiation Oncology*Biology*Physics, 1997
• Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of 4–20 ng/ml
  International Journal of Radiation Oncology*Biology*Physics, 1997
• Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate
  Radiotherapy and Oncology, 1996
• Prostate Specific Antigen as an Outcome Variable for T1 and T2 Prostate Cancer Treated by Radiation Therapy
  Journal of Urology, 1994
• Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time
  International Journal of Radiation Oncology*Biology*Physics, 1993
• Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy
  Cancer, 1993
• Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate
  Journal of Urology, 1991